On November 9, 2017 Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported that it will host an Investor Day on Thursday, November 16, 2017, from 8:30 a.m. to 10:30 a.m. ET in New York City (Press release, Kura Oncology, NOV 9, 2017, View Source;p=RssLanding&cat=news&id=2316024 [SID1234521878]). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, and Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will provide a comprehensive overview of the company’s clinical development program for its lead product candidate, tipifarnib, in HRAS mutant head and neck squamous cell carcinoma (HNSCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access a live audio webcast and slides of the presentations on the investor section of Kura’s website at www.kuraoncology.com beginning at 8:30 a.m. ET. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.